(Q40362040)

19 September 2017

title

Antitumor activity of a novel recombinant mutant human tumor necrosis factor-related apoptosis-inducing ligand (English)

1 reference

19 September 2017

Fang Fang

1

1 reference

19 September 2017

Ai-ping Wang

series ordinal

2

1 reference

19 September 2017

Shi-fang Yang

series ordinal

3

1 reference

19 September 2017

publication date

1 November 2005

1 reference

Acta Pharmacologica Sinica

19 September 2017

published in

1 reference

19 September 2017

volume

26

1 reference

19 September 2017

issue

11

1 reference

19 September 2017

page(s)

1373-1381

1 reference

Programmed cell death in animal development

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

Apoptosis: cell death in tissue regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

The pathogenic roles of tumor necrosis factor receptor p55 in acetaminophen-induced liver injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

Fas Ligand-dependent and -independent mechanisms of toxicity induced by T cell lymphomas in lymphoid organs and in the liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

Identification and characterization of a new member of the TNF family that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

TRAIL/Apo2L ligands induce apoptosis in malignant rhabdoid tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

Enhancement of Apo2L/TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-induced apoptosis in non-small cell lung cancer cell lines by chemotherapeutic agents without correlation to the expression level of cellular protease caspase-8 inh

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

Interleukin 1 beta-converting enzyme related proteases/caspases are involved in TRAIL-induced apoptosis of myeloma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

TRAIL/Apo-2L: mechanisms and clinical applications in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1745-7254.2005.00206.X

10.1111/J.1745-7254.2005.00206.X

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

19 September 2017

1008879035

0 references

1 reference